title: Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian carcinoma.
authors.forename: J P
authors.initials: JP
authors.lastname: Micha
authors.forename: J V
authors.initials: JV
authors.lastname: Brown
authors.forename: M A
authors.initials: MA
authors.lastname: Rettenmaier
authors.forename: L N
authors.initials: LN
authors.lastname: Abaid
authors.forename: A A
authors.initials: AA
authors.lastname: Mendivil
authors.forename: K L
authors.initials: KL
authors.lastname: Lopez
authors.forename: B H
authors.initials: BH
authors.lastname: Goldstein
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D009503:Neutropenia / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim